Kornimate/medical-research-clean huggingface dataset:
safety and effectiveness study of 532nm laser subthreshold panretinal photocoagulation for severe npdr

Conditions: Severe Non-proliferative Diabetic Retinopathy

Summary: this randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with pascal endpoint management function for severe non-proliferative diabetic retinopathy.

this randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with pascal endpoint management function for severe non-proliferative diabetic retinopathy : (1)to evaluate therapeutic effect of 532nm laser partially subthreshold panretinal photocoagulation with pascal endpoint management function for severe non-proliferative diabetic retinopathy; (2)to compare side effect of 532nm laser partially subthreshold panretinal photocoagulation with pascal endpoint management function on retina with traditional visible endpoint panretinal photocoagulation.

Eligibility criteria:
inclusion criteria: * diagnosis of severe non-proliferative diabetic retinopathy * age:45-80 years * best corrected visual acuity(bcva) ≥20/100,myopia≤-6 degree(-6d) * no photocoagulation (prp) before this clinical trial and no major ocular surgery (including cataract extraction, or any other intraocular surgery) within 3 months * ability and willingness to provide informed consent exclusion criteria: * participate in other clinical trials within 3 months * severe refractive media turbidity; unable to accept laser treatment such as nystagmus, etc * medically or mentally unstable(including cardiovascular disorders, cerebrovascular diseases,liver and kidney disease,hematological disorder and psychosis * conditions that in the opinion of the investigator would interfere trial results or increase risk * conditions that in the opinion of the investigator would preclude participation in the study

Keywords: severe non-proliferative diabetic retinopathy subthreshold panretinal photocoagulation pascal endpoint management
clinical study of neoadjuvant chemotherapy and immunotherapy combined with probiotics in patients with resectable nsclc

Conditions: Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage ⅢA; Non-small Cell Lung Cancer Stage IIIB

Summary: to evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for early resectable nsclc patients.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed previously untreated non-small cell lung cancer. patients with stage ii, iiia and potentially resectable stage iiib (t3n2) disease (according to ajcc 8th edition) are eligible ; * eastern cooperative oncology group (ecog) performance status score 0-1; * 18 years ≤ age ≤ 80 years. signed and dated written informed consent must be provided by the patient prior to admission to the study; * patients with appropriate treatment compliance and could be followed-up correctly; * patients with measurable or evaluable diseases (according to recist 1.1); * patients must have the ability to swallow oral drugs; * patients with adequate pulmonary function capable of tolerating the proposed lung resection (as determined by the surgeon); * signed and dated written informed consent must be provided by the patient prior to admission to the study. exclusion criteria: * subjects with known alk translocations or egfr mutations. * subjects with active, known or suspected autoimmune disease. subjects with vitiligo, type i diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll; * subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; * patients with symptomatic ild (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included. if you have any questions, please contact the trial team; * patients with other active malignant tumors currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug; * patients who are inability to follow the procedures required in the protocol due to any medical, mental or psychological conditions; * prior treatment with an anti-pd-1, anti-pd-l1 or anti-ctla-4 antibody or any other antibodies or drugs that target t cell costimulation or immune checkpoint pathways; * known positive test for hepatitis b virus surface antigen (hbv sag) or hepatitis c virus ribonucleic acid indicating acute or chronic infection; * known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome; * patients with a history of allergy to study drugs or ingredients.
socio-economic, meteorological and environmental factors associated with the incidence of covid-19

Conditions: COVID-19

Summary: socio-demographic factors in relation to the diagnosis of covid cases are increasingly mentioned in the role of transmission, but unfortunately with a small number of conclusive publications on french data. our objective is to analyse the distribution of cases according to these factors and their possible role during the first 6 weeks of 2021 when the alpes maritimes was the department with the highest incidence rate. the collaboration between ars06 and the public health department in the field of covid-19 has made it possible to have a departmental bulletin for monitoring the evolution of the epidemic (incidence, screening, hospitalisation). knowledge of the socio-demographic, meteorological and environmental factors associated with the transmission of sars-cov2 would make it possible to reflect on how to act on these factors and to implement a public health policy.


Eligibility criteria:
inclusion criteria: any person, adult or not, residing in the alpes-maritimes between 03/01/2021 and 14/02/2021 with a covid-19 diagnosis. exclusion criteria: non resident in the alpes-maritimes
eeg monitoring in the emergency department

Conditions: Drug Overdose; Substance Abuse; Alcohol Abuse

Summary: this study seeks to investigate whether drug effects in suspected overdose patients could be identified using the electroencephalogram (eeg). from previous work it is known that different classes of anesthetic drugs have specific "eeg signatures" related to the drug mechanisms. many of the drugs of abuse that are frequently encountered in overdose patients are similar or identical to anesthetic drugs. the hypothesis for this study is that the eeg could be used to characterize the brain effects of intoxicants using eeg in the ed setting. such monitoring could one day help clinicians and first responders at the point-of-care make more informed decisions to improve the care of overdose patients.


Eligibility criteria:
inclusion criteria: * adult patients aged 18 years and older who present to the ed with suspected use of a potential drug of abuse exclusion criteria: * hemodynamic instability or other acute medical condition for which the primary treating team does not thing it would be appropriate or safe for the study staff to approach the patient * the patient has an overt head trauma or deformity of the face which would preclude application of the forehead eeg monitoring lead * the patient has dermatological issues or skin conditions on the forehead * the patient has known dementia and/or mental impairment * the patient is a prisoner * the patient is an employee or student at one of the study sites.

Keywords: electroencephalogram opioids alcohol benzodiazepines alpha-2 agonists propofol ketamine marijuana neuromechanisms of intoxicants
effects of dıfferent tournıques and posıtıons on paın, anxıety levels and applıcatıon success in perıpheral intravenous catheter applıcatıon: a randomızed controlled study

Conditions: Tourniquets; INTRAVENOUS CATHETER APPLICATION

Summary: aim: the aim of this study was to investigate the effect of different tourniquet and position on pain, anxiety level and success of peripheral intravenous catheter (pic) application. design: randomized controlled experimental design.

aim: the aim of this study was to investigate the effect of different tourniquet and position on pain, anxiety level and success of peripheral intravenous catheter (pic) application. primary purpose:investigate the effect of different tourniquet and position on pain, secondary purpose:investigate the effect of different tourniquet and position on anxiety level and success of peripheral intravenous catheter (pic) application. design: randomized controlled experimental design. methods: the randomized controlled experimental design study was conducted with 110 adult patients in the orthopedic department of a training and research hospital between may 2024 and july 2024. data were collected using the patient information form, visual infusion phlebitis diagnostic scale, infiltration scale, visual pain scale, and facial anxiety scale. pic was applied to patients in the "experimental group 1" using a standard tourniquet in the supine position, to patients in the "experimental group 2" using a sphygmomanometer at 60 mmhg pressure in the fawler position, and to patients in the "experimental group 3" using a sphygmomanometer at 60 mmhg pressure in the supine position. in the control group, a peripheral intravenous catheter was applied in the fawler position using a standard tourniquet. patients were asked to evaluate the level of pain and anxiety before and after the application. the patients were followed up for phlebitis and extravasation findings at eight-hour intervals after the application. except for complications requiring removal of the peripheral intravenous catheter during follow-up, the pic was removed 96 hours after application. the results were evaluated at 95% confidence intervals with a significance level of p ≤ 0.05.

Eligibility criteria:
inclusion criteria: * patient 1. volunteering to participate in the research 2. be between the ages of 18-64, 3. the planned length of hospitalization is not less than 96 hours. exclusion criteria: in the patient 1. coagulation, hematologic and hydration problems 2. oncological, allergic diseases, any incision or scar tissue in the antecubital area, presence of complications due to a previously opened catheter, presence of pain, hematoma, ecchymosis in the application area, or presence of any other injection in the antecubital area on treatment days, 3. the presence of an obstacle (such as mastectomy) in the arm to be treated. expulsion criteria from the study: 1. dislodgement of the peripheral intravenous catheter for any reason. 2. failure of peripheral intravenous catheter placement more than twice. 3. discharge of the patient from the hospital.

Keywords: peripheral catheterization; tourniquet; pain; anxiety
impact of the coronavirus (covid-19) on patients with cancer

Conditions: Cancer; COVID-19

Summary: the purpose of this study is to understand the impact of covid-19 on patients with cancer through a survey.

the global spread of coronavirus (covid-19) is affecting cancer patients and their treatments. cancer patients are among those at high risk of developing serious illness from an infection because their immune systems are often weakened by cancer and its treatments. due to the growing coronavirus outbreak, patients clinic visits are being cancelled and many are facing social isolation and strict restrictions on their daily lives. we want to evaluate the impact of the coronavirus on the patient's well-being and their cancer care by assessing the delays in their medical care and any other unmet needs. we have created a survey that is available online for any patient with cancer to fill out voluntarily regarding their experiences to date. the survey is available at: https://stanforduniversity.qualtrics.com/jfe/form/sv_ctks6zsmydeyoxx

Eligibility criteria:
inclusion criteria: 1. the patients must be 18 years or older. 2. patients who opt in to complete the survey. 3. patients must have the capacity to verbally consent for the interview. exclusion criteria: 1.patients who under the age of 18 years old.

Keywords: coronavirus covid-19 cancer life change events
the effect of distraction with a kaleidoscope on the level of perceived pain during blood sampling in children

Conditions: Pain

Summary: this experimental study aimed to determine the effect of distracting children with a kaleidoscope during blood sampling on their perception of pain during the procedure and to increase and improve the quality of evidence for the effectiveness of these methods across different populations and cultures. hypothesis 0 (h0): there is no difference between the pain scores of the kaleidoscope group and the control group during blood sampling. hypothesis 1 (h1): there is a difference between the pain scores of the kaleidoscope group and the control group during blood sampling.

a pain-free life is the right of every child. eliminating pain and improving the quality of life of children is one of the main goals of nursing care. pediatric nurses should choose the appropriate assessment tool for the child's age and developmental characteristics and diagnose pain correctly. for this purpose, nurses can use appropriate distraction methods. since the nurse is the healthcare worker who is with the child and family the most throughout the day, s/he should closely monitor and evaluate the child's pain and inform the child and family about the principles of pain control. many hospitals in türkiye generally do not use any non-pharmacologic methods to reduce procedural pain. given that distraction techniques are inexpensive and easy to use, and that reducing children's pain may reduce negative feelings towards future procedures, it is important to examine the effectiveness of such methods. in our study, a kaleidoscope, one of the methods of distraction to reduce pain during blood sampling in children, was used. a kaleidoscope is a game tool that helps distract the child's attention from procedural pain and shows the external image by reproducing it when viewed through it. this experimental study aimed to determine the effect of distracting children with a kaleidoscope during blood sampling on their perception of pain during the procedure and to increase and improve the quality of evidence for the effectiveness of these methods across different populations and cultures.

Eligibility criteria:
inclusion criteria: * were being 7-12 years of age * not having an auditory or visual disability * not taking analgesics in the last eight hours * not having any pain caused by other reasons before the procedure * having vascular access and blood sampling interventions exclusion criteria: * having physical or mental disability * having any nerve damage

Keywords: blood collection distraction non-pharmacological treatment pain schoolchild
unity-based mr-linac adaptive simultaneous integrated hypofractionated boost trial for high grade glioma in the elderly

Conditions: Glioblastoma Multiforme, Adult; Glioblastoma, IDH-mutant

Summary: the usual standard of care for patients over 65 diagnosed with glioblastoma ("gbm") or grade 4 astrocytoma, idh-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (tmz). this radiation dose and length of treatment are less than what would be given for younger patients, primarily due to unclear survival benefits from randomized trials. however, survival remains dismal, and may be partially due to the reduced radiation dose. recent studies investigating this have found that increased radiation dose (to the equivalent of what is normally given over 6 weeks in younger patients) over 3 weeks is well-tolerated and has improved survival rates. additionally, with the advent of novel technology such as the mr-linac, adaptive radiotherapy with this regimen using reduced radiation margins is possible. use of the mr-linac allows for daily mri scans to be done prior to treatment, so plans can be adapted to tumour dynamics and anatomical deformations. in this trial, we will examine the outcomes of increased radiation dose, combined with reduced-margin adaptive radiotherapy in this patient population.


Eligibility criteria:
inclusion criteria: * patient age ≥ 65 years * histopathologically confirmed, based on biopsy or surgical resection, glioblastoma or who grade 4 astrocytoma, idh-mutant * biopsy or surgical resection performed ≤ 6 weeks prior to study entry * deemed suitable by the treating physicians for 15 daily fractions of radiation, delivered daily over 3 weeks, with concurrent temozolomide chemotherapy * expected survival ≥ 12 weeks * ecog performance status of 0, 1 or 2 * able (sufficiently fluent in english) and willing to complete qol questionnaires; however, inability to complete the questionnaires will not make the patient ineligible for the study * sufficient estimated glomerular filtration rate (egfr) of ≥ 30 ml/min/1.73 m2 to allow administration of gadolinium-based contrast agent; patients with egfr \< 30 ml/min/1.73 m2 not on dialysis may be allowed on the study after discussion of risks and benefits and approval by study neuroradiologist(s) * completed written informed consent * patient must be accessible for treatment and follow-up exclusion criteria: * contraindications to mri as per standard mri screening policy * contraindication to gadolinium-based contrast media * inability to lie flat in a supine position for at least 90 minutes * inability to tolerate immobilization in a head thermoplastic mask * patients \> 140 kg and/or a circumference \> 60 cm * prior dose-limiting cranial irradiation * t1w post-gadolinium enhancing disease involving the brainstem * leptomeningeal dissemination of disease * patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol
multiple-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of bms-779788 in healthy subjects

Conditions: Atherosclerosis

Summary: the primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of bms-779788 in healthy subjects


Eligibility criteria:
inclusion criteria: * men and women (not of child bearing potential) ages 18 to 45 * healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ecgs, and clinical laboratory determinations exclusion criteria: * women of child bearing potential * evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ecg or clinical laboratory determinations
clinical efficacy of self-adhesive silicone gel waterproof dressings versus conventional dressings in the healing of incisions after total joint arthroplasty

Conditions: Self-adhesive Silicone Gel Waterproof Dressing; Gauze Dressing; Total Joint Arthroplasty

Summary: the efficacy of using self-adhesive silicone gel waterproof dressings versus conventional gauze dressings for recovery after total joint arthroplasty (tja) remains unclear. in our study, we conducted a prospective, randomized controlled trial to compare these two types of dressings. patients were divided into two groups following tja, and we collected primary outcome measures such as skin infection rate and re-operation rate. additionally, we gathered blood inflammatory indicators, including c-reactive protein (crp) and erythrocyte sedimentation rate (esr), to evaluate the effectiveness of the two treatments. finally, we perform one year follow up including reeda score, mss score to evaluate the recovery of the skin.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, gender is not limited; 2. meet the diagnostic criteria for artificial joint replacement; 3. initial joint replacement surgery; 4. voluntary and signed informed consent. exclusion criteria: 1. allergic to self-adhesive silicone rubber waterproof dressing; 2. patients with severe knee joint infection who cannot undergo artificial joint replacement; 3. progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30ml/min; 4. periprosthesis infection after multiple joint replacement; 5. active infection at the site of intravenous or joint injection; 6. long-term use of anticoagulants or antiplatelet drugs due to other diseases; 7. have sepsis or positive blood culture within the last 30 days; 8. radiotherapy and chemotherapy are required due to neoplastic diseases; 9. receiving systemic glucocorticoid therapy (prednisone \> 10mg/ day or equivalent hormone medication); 10. severe immunodeficiency diseases (such as stage 3 hiv, sickle cell anemia, splenectomy, etc.); 11. have a history of drug abuse; 12. treatment of bone marrow or other transplants with immunosuppressive drugs; 13. pregnant, parturient and lactating women; 14. participating in other clinical trials; 15. researchers believe that other reasons are not appropriate for clinical trial participants.

Keywords: self-adhesive silicone gel waterproof dressing gauze dressing total joint arthroplasty rct
ibi310 in combination with siltilimab in subjects with anti-pd-1/pd-l1 resistance r/m npc

Conditions: NPC

Summary: this is a phase 1b/ii, open label, multicenter study of ibi310 (anti-ctla4 mab) in combination with sintilimab in patients with recurrent/metastatic nasopharyngeal carcinoma that failed prior anti-pd-1/pd-l1 therapy


Eligibility criteria:
inclusion criteria: 1. aged ≥18 years; 2. ecog 0 \~ 1; 3. histologically/cytologically confirmed r/m npc; 4. failed to prior anti-pd-1 resistance; 5. adequate organ and bone marrow function; 6. expected survival ≥12 weeks; 7. female subjects of childbearing age or male patients whose sex partners are women of childbearing age should take effective contraceptive measures throughout the treatment period and within 6 months after the last administration; 8. subjects who sign the written informed consent form, and can abide by the visits and related procedures specified in the protocol. 9. at least 1 measurable lesion according to the response evaluation criteria in solid tumors version 1.1(recist v1.1). exclusion criteria: 1. had tumors other than npc within the past 5 years. 2. had allogeneic organ or stem cell transplantation. 3. the presence of uncontrolled life-threatening illness 4. women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. 5. patients who have used large doses of glucocorticoids, anti-cancer monoclonal antibodies, and other immunosuppressive agents within 4 weeks. 6. hiv positive. 7. patients with significantly lower heart, liver, lung, kidney and bone marrow function. 8. severe, uncontrolled medical conditions and infections. 9. at the same time using other test drugs or in other clinical trials. 10. refusal or inability to sign informed consent to participate in the trial. 11. other treatment contraindications. 12. emotional disturbance or mental illness, no civil capacity or limited capacity for civil conduct. 13. hepatitis b surface antigen (hbsag) positive and hbvdna ≥1000cps/ml. 14. patients with positive hcv antibody test results can only be included in the study when the polymerase chain reaction of hcv rna is negative.